Pharmacology and Biochemistry of Haloperidol
by Dr Carlos J E Niemegeers and Dr Pierre M Laduron (Research Laboratories, Janssen Pharmaceitica, Beerse, Belgium) Haloperidol (Fig 1) was synthesized in the research laboratories of Janssen Pharmaceutica in February 1958 (Janssen 1970 . At that time psychopharmacology and neurobiochemistry were still relatively unexplored fields. Since the discovery of haloperidol 2213 scientific papers concerning this drug have been published, of which 139 are related to its biochemistry, 633 to its pharmacology and 1441 to its clinical efficacy. In this way haloperidol, as a scientific tool, has contributed to a large extent to the historical development of psychopharmacology and of neurobiochemistry and, clinically, it has become a major implement in the evolution of modern psychiatry.
In spite of the enormous progress made during the past two decades in the better understanding of various functions of the brain, many basic problems remain unsolved today. Psychiatry is still faced with the fact that the anatomical and biochemical basis of schizophrenia is unknown. Moreover neuroleptics are mainly used and considered as a purely palliative treatment, designed to alleviate overt symptoms, while, if properly titrated, they may well normalize the psychotic state of the patient by interfering with a neurotransmitter in a given brain area.
On the other hand, except for amphetamineinduced behaviour, which is believed to mimic human psychosis to a certain extent, psychopharmacology still lacks a suitable animal model for the measLtrement of antipsychotic effects. Finally, although there is an overwhelming amount of evidence to support the concept that the pharmacological effect of neuroleptics derives from their blockade of the dopamine receptors, these have never actually been isolated, so that the precise mechanism of action of neuroleptics with regard to their antipsychotic effect remains uncertain and the exact area of the brain responsible for psychotic disorders is, as yet, unidentified.
Nevertheless, since the clinical discovery of the first neuroleptics, and in spite of all the unknown factors, a number of new drugs were developed by means of pharmacological tests and were used successfully in the treatment of schizophrenia. The aim of the present paper is to outline and to comment on the most important pharmacological and biochemical methods currently used in the study of neuroleptics, to which haloperidol, as a standard reference compound, has made a major contribution.
Pharmacology
All neuroleptics have certain common properties when given to animals. In rats, neuroleptics antagonize stereotyped behaviour and agitation induced by apomorphine and amphetamine; they slow down and inhibit learned intracranial selfstimulation and conditioned reactions; they reduce exploratory behaviour and spontaneous motility and they antagonize tryptamine-induced effects and protect from norepinephrine-induced toxicity. Furthermore neuroleptics produce catalepsythat is a tendency to maintain abnormal body postures in the absence of muscular rigidity
M.W.:375.86 or hypnosis. They produce palpebral ptosisthat is, drooping of the upper eyelidand they induce hypotonia, sedation, prostration and hypothermia (Janssen 1972 , Janssen & Niemegeers 1961 , Janssen, Niemegeers & Jageneau 1960 , Janssen et al. 1963 , Janssen et al. 1965a , Janssen et al. 1967 , Niemegeers et al. 1969 , 1970a , b, Wauquier & Niemegeers 1972 ). Nearly all these phenomena observed in rats are also observed in mice, in monkeys and in dogs, but in the dog the most striking effect of all known typical neuroleptics is that they antagonize apomorphine-induced vomiting (Janssen 1972 , Janssen, Niemegeers & Schellekens 1960 , 1965b , Janssen et al. 1963 , Niemegeers 1971 , 1965 .
A new drug which, to a greater or lesser extent exhibits most of the aforementioned properties, will be classified by the pharmacologist as a neuroleptic, although neuroleptics may present many other effects as well and, as always, exceptions may prove the rule.
The described effects, however, do not all occur simultaneously at the same dose levels and clinically important qualitative differences may be inferred from these dosage interrelations. This particular point is illustrated in somewhat more detail by comparing the activity profile of haloperidol with that of chlorpromazine. Table I shows the ED50 values in mg/kg after subcutaneous administration of haloperidol and chlorpromazine in the different tests already mentioned. It has been shown empirically that there is a good correlation between antipsychotic efficacy in man and the ability of a drug to block, at low doses, apomorphine-induced stereotypy in rats. Apomorphine is believed to bring about a direct activation of central dopamine receptors and, as shown in Table 1 , 0.02 mg/kg of halo- (450) peridol and 0.30 mg/kg of chlorpromazine are the lowest doses detectable in rats without any demonstrable effect on general behaviour. Antagonism of amphetamine (an indirect dopamine stimulating agent) and inhibition of conditioned reactions appear at approximately twice the anti-apomorphine dose level in both haloperidoland chlorpromazine-treated rats. Cataleptic immobility, a behavioural phenomenon that could be considered as a criterion for the evidence of neurological effects of the drug, is induced at 0.20 mg/kg of haloperidol and at 2.40 mg/kg of chlorpromazine. Here again haloperidol closely resembles chlorpromazine. A first relative difference between the two drugs is seen in their ptosis-inducing activity and in their antagonism to tryptamine. Presumably these activities are related to hypnosedation, drowsiness or somnolence. Therefore we usually expect hypnosedation to occur with chlorpromazine, whereas with haloperidol it will only appear at dosages much higher than the effective antipsychotic dose. Another important distinction between both compounds is their a-adrenergic blocking potency, as measured in the norepinephrine test and their hypothermia-inducing properties. Haloperidol is virtually devoid of any activity in this respect, in contrast to chlorpromazine in which the adrenolytic and antipsychotic doses are nearly equal. Therefore autonomic sideeffects, such as orthostatic hypotension, tachycardia and other symptoms of autonomic blockade will be difficult to avoid at therapeutic dose levels of chlorpromazine.
Like most neuroleptics, haloperidol and chlorpromazine are relatively nontoxic. Nevertheless, the safety margin (that is, the ratio between the lowest active dose and the lethal dose) is 3000 for haloperidol, but only 450 for chlorpromazine. The basis of the test is straightforward: a standard dose of apomorphine induces vomiting in all control dogs and pretreatment with a neuroleptic blocks the emetic effect of the same high dose of apomorphine. Fig 2 (left) shows the effect of haloperidol after subcutaneous injection and after oral administration in the antiapomorphine test in dogs. The doses indicated are the ED50 values with confidence limits in mg/kg obtained at regular intervals after administration of haloperidol, from a quarter of an hour up to 64 hours. Given subcutaneously, the onset of action of haloperidol is very fast. Given orally the onset is somewhat slower and reaches its peak effect four hours after administration.
By both routes the duration of action of haloperidol is long. As measured by this test it is up to 64 hours. From the fourth hour, haloperidol is equipotent subcutaneously and orally, the effective doses being approximately 0.03 mg/kg, indicating a very high degree of potency and a nearly perfect oral absorption. Fig 2 (right) shows the time-effect curves for chlorpromazine. Chlorpromazine reaches its peak effect one hour after subcutaneous, and two to four hours after oral administration. The effective doses of chlorpromazine are approximately 0.70 mg/kg and 4.00 mg/kg for subcutaneous and oral administration respectively. Thus chlorpromazine is much less potent than haloperidol; its oral absorption is relatively poor and its duration of action, as shown in Fig 2, is much shorter than that of haloperidol.
To summarize, from this pharmacological data in animals we may conclude that neuroleptics differ pharmacologically in their potency, onset and duration of neuroleptic activity, in oral versus parenteral absorption, in their specificity, side effect liability and toxicity. Neuroleptics are either potentthat is active at low dose levelsor weak. Haloperidol is a potent and chlorpromazine a weak neuroleptic. Whereas the onset of action is rapid for both compounds, the duration is long with haloperidol and short with chlorpromazine. The oral absorption of chlorpromazine is poor while that of haloperidol is good. Neuroleptics are either typical or atypical. At neuroleptic dose levels, an atypical neuroleptic produces other non-neuroleptic effects, such as a-adrenergic inhibition and sedation. Haloperidol is a typical and chlorpromazine an atypical neuroleptic. As a rule the most potent neuroleptics are the most typical or specific and also the least toxic ones.
Biochemistry
It is widely accepted that neuroleptics can block dopamine (DA) receptors (Anden et al. 1970 , Van Rossum 1966 . They do so, presumably by a feed-back mechanism which brings about an increase in the turnover of dopamine in the brain. Although the most direct arguments for this dopamine blockade are biochemical ones (Table 2) , there is also some indirect evidence suggested by pharmacological tests and clinical observations (Laduron 1971) .
For instance, antagonism in the apomorphine and amphetamine tests may be considered as indirect evidence of dopamine blockade since apomorphine is considered to mimic the effects of dopamine and amphetamine produces a release of dopamine from dopaminergic terminals (Ernst 1967 , Munkvad et al. 1968 ). Similarly, the results obtained in the turning test, using rats with a lesioned striatum, are considered to be related to the presence of dopaminergic transmission (Anden et al. 1970) . Clinical evidence for an interaction of neuroleptics with dopaminergic neurones may be assumed from the parkinsonian symptoms in patients treated with neuroleptics (Hornykiewicz 1966).
The first more direct biochemical evidence for a dopaminergic involvement of neuroleptics was provided by the observation that 3-methoxytyramine (Carlsson & Lindqvist 1963) and homovanillic acid (HVA) (Anden et al. 1964 , Gerardy & Dresse 1974 , O'Keeffe et al. 1970 ) were found to be increased in the brain of different animal species after treatment with neuroleptics. More recently HVA was also measured in the cerebrospinal fluid (CSF) of treated patients and the increase of HVA was found to be strongly correlated with the amelioration of the psychotic symptoms (Sedvall et al. 1975 , Van Praag & Korf 1976 .
This could indicate a relationship between improvement of the patients and dopamine receptor blockade. It has been shown in experiments using labelled precursors of catecholamines and measuring the rate of radioactive dopamine appearance that increased HVA is really due to an increase in the rate of dopamine synthesis without affecting the content of endogenous dopamine (Nyback & Sedvall 1970 , Persson 1970 . It is, however, not clear whether this increase of synthesis is related to changes of kinetic constant of tyrosine hydroxylase (Zivkovic & Guidotti 1974) . The recent finding that neuroleptic drugs can inhibit the production of dopamine on stimulated cyclic adenosine monophosphate (cAMP) seems to shed more light upon the concept that dopamine receptors in the brain may be related to the action of neuroleptic drugs (Clement-Cormier et al. 1974 . Only the cAMP production stimulated by dopamine is inhibited by haloperidol.
Many neuroleptics were found to inhibit the dopamine-sensitive adenylate cyclase although a good quantitative correlation with the pharmacological activity of the drugs was not always obtained. The relatively poor solubility of some neuroleptics, which constitutes a limiting factor in this in vitro test, may be responsible for this discrepancy (Laduron 1976) . Moreover, the pharmacological activity of neuroleptics is a result of a sequence of events which involves absorption, distribution, metabolism, crossing of the blood-brain barrier, specific uptake in a given area and affinity towards receptors. Taking this into account it seems logical to admit that a perfect correlation between effects in vitro and in vivo will not always be possible but will merely be limited to a given series of drugs which have the same physicochemical properties. As such, a very convincing correlation between the dopaminesensitive adenylate cyclase antagonism and apomorphine antagonism was recently found for a group of 20 compounds derived from haloperidol ).
Besides its action on dopaminergic neurones, haloperidol was found to decrease the content of acetylcholine in the rat striatum, an effect that seems to be due to a higher release of the neurotransmitter (Guyenet et al. 1975 ). This property may be directly related to the blockade of dopamine receptors since the nigrostriatal pathways display an inhibitory effect on cholinergic interneurones of the striatum.
That haloperidol affects the dopamine turnover is illustrated in Fig 3. Various doses of haloperidol were injected into rats and the HVA content in the rat brain was measured four hours after a single injection or after chronic administration for eight days. There was a dose-related increase in HVA, when haloperidol was given once. Interestingly, the increase in HVA after high doses of haloperidol was much less pronounced after chronic treatment than after acute injection of the saine doses. Tolerance, with regard to the antipsychotic effects of haloperidol, has never been reported, whereas Parkinson-like side-effects were often found to disappear during long-term therapy. This consideration opens up the possibility of an adequate individualized dosage schedule for haloperidol, especially for increasing the dose in the course of the therapy. This tolerance phenomenon to HVA is not common to all neuroleptics. It seems that the less active, more sedative and more toxic ones are devoid of this property. Therefore, this tolerance phenomenon seems to be a particularly favourable characteristic of neuroleptics in contrast to barbiturates and narcotics, in which it is considered to be a major drawback.
Finally, stereospecific binding experiments recently described for neuroleptics, but already developed and widely used for narcotic analgesics, might probably provide in the future a useful tool for determining the exact part of the brain in which neuroleptics act (Burt et al. 1975 , Seeman et al. 1975 .
Conclusion
Neuroleptic activity cannot be adequately presented by means of a single test procedure in animals, but should, in fact, be defined in terms of 'neuroleptic activity profiles'. Such pharmacological and biochemical profiles should permit a more reasonable prediction of: clinical efficacy; specificity; potency; onset and duration of action of neuroleptic activity; oral and parenteral absorption; side-effect liability and toxicity; and to some extent a better understanding of the mechanism of action of these drugs. Comparing the activity spectra of all known neuroleptics studied pharmacologically and biochemically, none of those available in the clinic possesses intrinsically so many favourable properties as haloperidol. Therefore haloperidol may be considered as having a unique profile and this is probably the reason for its continued success as the mainstay of modern psychiatry. Van Dr Niemegeers said the effects that he had demonstrated were those of tryptamine injected intravenously into rats at the relatively high dose of 40 mg/kg. Intravenous tryptamine produced a series of central effects together with peripheral ones. His paper had considered both of them.
It was assumed that tryptamine and serotonin were related in this respect. He believed that the tryptamine blocking activity of the drug was related to its sedative effect. Most of the sedative neuroleptics blocked the central tryptamine effect, although they might also block some of the peripheral effects. Blocking of centrally induced tryptamine effects required doses of sedative neuroleptics of about the same order as those needed to block the central anti-apomorphine effect. Dr C B de White (London) asked what was the relative potency of haloperidol compared with other neuroleptics in terms of anti muscarinic activity. Dr Niemegeers believed that haloperidol had no antimuscarinic anticholinergic activity. If in the laboratory a neuroleptic agent was given together with a central anticholinergic substance the result in many instances was to reduce the neuroleptic effect. He did not think it advisable to use mixtures of such substances.
Dr A 0 Forsman (Gothenblurg) commented on the specific retention of haloperidol in dopamine receptors. He questioned the methodology used in confirming this effect since his own investigations with gas liquid chromatography had revealed no differences in parts of the brain rich in these receptors if they were compared to other parts. There was a nonspecific retention in the whole of the brain and also in any liquid-rich tissue in the body. Dr Niemegeers was unable, off-hand, to comment on the exact methodology. But similar retention in dopaminergic systems had been demonstrated by the Biochemical Division of the Janssen Research Laboratory with pimozide, penfluridol and clopimozide. Dr S J Dencker (Gothenburg) commented on the difference in homovanillic acid in the acute and chronic phase in the rat. He compared it to the human situation in which more parkinsonian symptoms were found in the acute phase than in the chronic, at the same drug dose level. He wondered whether some difference in the nervous system or whether some actual adaptation was responsible.
Dr Niemegeers said the tolerance to increase in homovanillic acid after chronic administration had been shown for various neuroleptics though not for all. So far it had been associated largely with the neuroleptic effects, though not the extrapyramidal side-effects of these drugs. With the more sedative neuroleptics, and indeed the more toxic neuroleptics, such a decrease after chronic administration was not obtained.
